Abstract
Although cyclopropanation with donor/acceptor carbenes can be conducted under low catalyst loadings (<0.001 mol %), such low loading has not been generally effective for other classes of carbenes such as acceptor carbenes. In this current study, we demonstrate that ethyl diazoacetate can be effectively used in the cyclopropanation of N-Boc-2,5-dihydropyrrole with dirhodium(II) catalyst loadings of 0.005 mol %. By appropriate choice of catalyst and hydrolysis conditions, either the exo- or endo-3-azabicyclo[3.1.0]hexanes can be formed cleanly with high levels of diastereoselectivity with no chromatographic purification.
Saturated nitrogen heterocycles are ubiquitous in pharmaceutical drugs and play an increasing role in drug discovery with the current emphasis on nonplanar structures as potential drug targets.1 In recent years there has been considerable interest in small bicyclic scaffolds because they orientate key pharmacophores in well-defined three-dimensional space.2,3 One such core structure is the 3-azabicyclo[3.1.0]hexane-6-carboxylate scaffold 1. Several lead compounds and drug candidates have been developed incorporating this structural motif as illustrated with 2–7 (Scheme 1).4−10
Scheme 1. Pharmaceutical Relevance of 3-Azabicyclo[3.1.0]hexanes4−10.
Considering the pharmaceutical significance of 1, a plethora of methods11 have been developed for its synthesis but one obvious method, the cyclopropanation of 2,5-dihydropyrrole with ethyl diazoacetate (EDA), even though it has been explored by several groups,4,6,8,10,12−16 still needs considerable improvement (Scheme 2A). The published procedures require 1–7 mol % rhodium acetate as catalyst, and the resulting yields range from 8 to 66%. In recent years, great advances have been made in generating diazo compounds in flow,17−24 so the main remaining challenge is to improve the efficiency of the rhodium-catalyzed reaction. The Davies group has had a long-standing interest in the chemistry of donor/acceptor carbenes and has shown that cyclopropanation with these carbenes can be routinely conducted with very low catalyst loadings (<0.001 mol %).25−28 Therefore, we decided to embark on a collaborative study to determine whether the information gained about donor/acceptor carbenes could be applied to acceptor carbenes and, thus, achieve a practical entry to either diastereomer of the azabicyclic scaffold 1 (Scheme 2B). The results of this study are described herein.
Scheme 2. Previous Work [A] versus Current Work [B] on Dirhodium(II)-Catalyzed Cyclopropanation of N-Boc-2,5-Dihydropyrrole with EDA.
The dirhodium(II)-catalyzed intermolecular cyclopropanation with donor/acceptor carbenes is generally far superior to the corresponding reaction with acceptor carbenes, such as the carbene derived from EDA. Highly diastereoselective and enantioselective reactions are routine (>20:1 d.r.),26 and we have reported that the turnover numbers (TONs) with donor/acceptor carbenes are vastly superior compared to acceptor carbenes.27 Fortunately, enantioselectivity is not an issue in the current study since exo/endo-1 is meso. Furthermore, even if the diastereoselectivity is poor, equilibration could be possible under basic conditions to favor the thermodynamic exo-1 diastereomer. Thus, the major question that needed to be addressed is whether the recent advances in catalyst design and the general understanding of rhodium–carbene chemistry could be applied to greatly increase the turnover efficiency of acceptor carbenes such that a commercially competitive process could be developed to access this pharmaceutically valuable scaffold. Our studies on high TON catalysis with donor/acceptor carbenes have revealed the following trends that are useful for the design of the current study: (1) An effective trapping of the carbene is required to achieve high TON, which means excess of trapping agent is beneficial.27 (2) Generally, trichloroethyl diazoacetate performs better than EDA.26 (3) Dimethyl carbonate (DMC) is more effective and environmentally friendly than dichloromethane.26 (4) Elevated temperatures enhance overall efficiency.25 (5) Bridged tetracarboxylate ligands confer greater stability to the catalysts.28
Using these trends as guiding principles, we conducted an optimization study for the cyclopropanation of N-Boc-2,5-dihydropyrrole 9. The initial studies were conducted with EDA 10 using 1 mol % of the more commonly used achiral dirhodium(II) tetracarboxylate catalysts as well as the bridged dirhodium(II) catalyst Rh2(esp)2.29 In the previous studies, EDA 10 was used as the limiting agent4,6,8,10,12−16 because the dihydropyrrole 9 was relatively more expensive. As we wished to focus on enhancing the TON, we used an excess of the trap 9, and furthermore, we used DMC as an environmentally benign replacement solvent to dichloromethane.30 Under these conditions, all the catalysts performed well giving exo/endo-1 in 63–79% yield, although in most cases, the reaction gave a 1:1 mixture of the exo and endo diastereomers (Scheme 3). These results, in comparison to the previous literature studies,4,6,8,10,12−16 demonstrate that an excess of trapping agent would be advantageous when studying protocols for high TON transformations (see Table S1 for catalyst structures and complete optimization studies).
Scheme 3. Cyclopropanation with Excess Trap.
We then took on the more demanding challenge of conducting cyclopropanation with a much lower catalyst loading. We determined a catalyst loading of 0.005 mol % would be an appropriate target because, at such low catalyst loadings, the fluctuating cost of rhodium would not be especially impactful on the overall cost of the process (see Figure S13 for details). The results of the optimization study are summarized in Table 1. When the reaction was conducted at room temperature, exo/endo-1 was produced in a low yield (entry 1). In the case of the donor/acceptor carbenes, we found that the optimum temperature for high TON was 60–70 °C.25,26 When the reactions with 10 were conducted at 70 °C, the yields of the cyclopropanation were still relatively low (9–32%) and the crude NMR showed evidence of unreacted EDA 10 (entries 2–5). The optimum catalyst in this study was the bridged tetracarboxylate catalyst Rh2(esp)2.
Table 1. Optimization of Low Catalyst Loading and High TON with Achiral Dirhodium(II) Tetracarboxylates (Reactions Were Run at 0.500 mmol).
qHNMR yield analysis with 1,3,5-trimethoxybenzene.
d.r. was calculated from crude 1H NMR.
For calculations, refer to the Supporting Information.
6 h slow addition (tr = 8.5 h) instead.
The total reaction concentration is 0.5 M.
The total reaction concentration is 1 M.
4 Å molecular sieve is absent.
10 mmol reaction was performed.
15.7% EDA 10 in toluene was used instead of 74% EDA 10 in CH2Cl2.
Trichloroethyl diazoacetate was used instead of EDA 10.
Isolated yield.
Further optimization of the Rh2(esp)2-catalyzed reaction was conducted at 90 °C, and under these conditions, the yield of exo/endo-1 greatly improved to 76% (entry 8). In the case of aryldiazoacetates, the trihaloethyl esters often gave better performance,26 but with diazoacetates, this was not the case as the trichloroethyl derivative actually gave lower yield (entry 11). As these reaction temperatures are relatively high, control experiments were conducted in the absence of the catalysts (entries 12 and 13), which revealed that the products are not being formed under purely thermal conditions because EDA 10 remained unchanged. The reaction was scaled up to gram scale, and as is typical of this chemistry, the isolated yield was significantly improved in the larger scale reaction (90% isolated yield, entry 14). Exo/endo-1 was cleanly isolated through Kugelrohr distillation, and no chromatographic purification was needed. The commercially available EDA 10, dissolved in toluene, was also evaluated as the carbene source, but this was inferior (entry 15) because a reaction between the carbene and toluene competed with the desired cyclopropanation.
The next series of experiments were directed toward exploring whether the diastereoselectivity of the process could be directed toward the thermodynamically less favored endo-1 diastereomer (Table 2). As previously described, the achiral catalysts were relatively unselective, resulting in close to a 1:1 exo/endo mixture (Table 1). However, when the reaction was conducted using some of our recently developed chiral bowl-shaped catalysts, the reaction could be directed to favor the thermodynamically less favorable endo isomer (see Table S2 for details). Two of the most impressive catalysts in the study were Rh2(S-TPPTTL)4 and its brominated derivative, Rh2[S-tetra-(3,5-di-Br)TPPTTL]4. Both catalysts were effective at a catalyst loading of 0.005 mol %. Rh2(S-TPPTTL)4 gave 59% yield and a 24:75 exo/endo ratio, and Rh2[S-tetra-(3,5-di-Br)TPPTTL]4 gave a 70% yield and a 17:83 exo/endo ratio of 1. Due to the promising results, the reaction catalyzed by Rh2[S-tetra-(3,5-di-Br)TPPTTL]4 was conducted on a gram scale resulting in the formation of exo/endo-1 in 83% isolated yield with the same 17:83 exo/endo ratio.
Table 2. Endo-Selectivity with Chiral Dirhodium(II) Tetracarboxylates (Reactions Were Run at 0.500 mmol).
qHNMR yield analysis with 1,3,5-trimethoxybenzene.
d.r. was calculated from crude 1H NMR.
For calculations, refer to the Supporting Information.
Reaction ran at 10 mmol.
Isolated yield.
The next series of experiments explored how to generate either the exo isomer or the endo isomer of 1 as a single diastereomer without resorting to any chromatographic purification (see Tables S3–S5 for detailed optimization studies). Treatment of a 1:1 mixture of exo/endo-1 with sodium tert-butoxide caused epimerization at the α-carbonyl stereocenter of the ethyl ester to generate exclusively exo-1, which can be hydrolyzed with aqueous sodium hydroxide to form exo-11 (Scheme 4A). Exo-11 was isolated cleanly after an extraction protocol in 86% overall yield for the two steps in a one-pot procedure. Alternatively, endo-11 could be obtained in pure form, starting from exo/endo-1, enriched in the endo isomer by a 17:83 exo/endo ratio by changing the reaction sequence. Treatment of exo/endo-1 with aqueous sodium hydroxide resulted in the selective hydrolysis of exo-1 to form carboxylate exo-11, and the resulting unreacted endo-1 could be obtained cleanly as a single diastereomer after extractions. An extended exposure of endo-1 to aqueous sodium hydroxide led to the clean formation of endo-11 (Scheme 4B).
Scheme 4. Strategy to Selectively Access Exo- and Endo-11.
Having generated efficient procedures to generate either exo- or endo-11, we then explored the possibility of telescoping the reaction sequence so that all three steps can be combined (Scheme 5). The crude reaction from a 10 mmol scale rhodium-catalyzed cyclopropanation was filtered to remove the molecular sieves, and then the solvent was concentrated in vacuo. The crude material was then subjected to either the tandem isomerization-exo-hydrolysis conditions to afford the exo-11 or the tandem selective hydrolysis followed by endo-hydrolysis to afford endo-11. Both telescoped sequences went very smoothly, generating either the exo-11 in 76% combined yield or the endo-11 in 54% combined yield, without the need of any chromatographic purification and Kugelrohr distillation. Due to the significance of either the exo- or endo-3-azabicyclo[3.1.0]hexanes, the major focus of this study has been achieved, which is the selective formation of either stereoisomer beginning with a cyclopropanation with low catalyst loadings. Other substrates that worked well in the telescoped route are N-tosyl-2,5-dihydropyrrole 12, 2,5-dihydrofuran 13, and cyclopentene 14 to afford the corresponding exo-acid in overall combined yields ranging from 58 to 72% (exo-15, 16, and 17). The N-tosyl and N-Boc-2,5-dihydropyrroles (12 and 9, respectively) can be recovered in these strategies, recycled, and reused.
Scheme 5. Telescoped Expansion of Trap Scope to Afford Exo- and Endo-Acids.
All of these reactions were conducted on a 10 mmol scale to illustrate the scale-up potential of this chemistry. Furthermore, one of these reactions was followed by ReactIR and showed no accumulation of EDA 10 during the reaction (see Figures S6 and S7 for complete details).
In summary, these studies demonstrate that the cyclopropanation of 2,5-dihydropyrroles with EDA can be conducted with dirhodium(II) catalyst loadings as low as 0.005 mol %. These results illustrate that high turnover dirhodium(II) catalysis is not limited to donor/acceptor carbenes but can be extended to acceptor carbenes. Telescoped conditions were developed to enable the synthesis of either the exo- or endo-isomers of 3-azabicyclo[3.1.0]hexanes on a gram scale without requiring distillation or chromatographic purification, which demonstrates the practicality of the rhodium-catalyzed cyclopropanation for the synthesis of these valuable pharmaceutical intermediates.
Acknowledgments
We thank Eli Lilly’s Lilly Research Award Program (LRAP) for the generous funding. Constructive discussions within the Catalysis Innovation Consortium facilitated this study. At Emory University, we thank Dr. Bing Wang and Dr. Shaoxiong Wu for NMR measurements, Dr. John Bacsa for X-ray structure determination, and Dr. Fred Strobel for MS measurements. At Eli Lilly, we thank Dr. Shankar Vaidyaraman for generating and analyzing the cost-analysis chart.
Data Availability Statement
The data underlying this study are available in the published article and its Supporting Information.
Supporting Information Available
The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.orglett.3c03652.
Complete experimental procedures and compound characterization (PDF)
Author Contributions
The experimental work was conducted by Mr. Nguyen, following general guidelines and suggestions from Drs. Davies and Navarro. The manuscript was written through contributions of all authors.
The authors declare the following competing financial interest(s): T.-T.H.N., A.N., and H.M.L.D. are named inventors on a patent application related to this work.
Supplementary Material
References
- Lovering F.; Bikker J.; Humblet C. Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success. J. Med. Chem. 2009, 52, 6752–6756. 10.1021/jm901241e. [DOI] [PubMed] [Google Scholar]
- Garcia-Castro M.; Zimmermann S.; Sankar M. G.; Kumar K. Scaffold Diversity Synthesis and Its Application in Probe and Drug Discovery. Angew. Chem., Int. Ed. 2016, 55, 7586–7605. 10.1002/anie.201508818. [DOI] [PubMed] [Google Scholar]
- Prosser K. E.; Stokes R. W.; Cohen S. M. Evaluation of 3-Dimensionality in Approved and Experimental Drug Space. ACS Med. Chem. Lett. 2020, 11, 1292–1298. 10.1021/acsmedchemlett.0c00121. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kim J. H.; Nam G. Synthesis and evaluation of 6-pyrazoylamido-3N-substituted azabicyclo[3,1,0]hexane derivatives as T-type calcium channel inhibitors for treatment of neuropathic pain. Bioorg. Med. Chem. 2016, 24, 5028–5035. 10.1016/j.bmc.2016.06.006. [DOI] [PubMed] [Google Scholar]
- Coates D. A.; Remick D. M.. Preparation of novel SSTR4 agonist salts. WO2023044326, 2023.
- Biagetti M.; Leslie C. P.; Mazzali A.; Seri C.; Pizzi D. A.; Bentley J.; Genski T.; Fabio R. D.; Zonzini L.; Caberlotto L. Synthesis and structure–activity relationship of N-(3-azabicyclo[3.1.0]hex-6-ylmethyl)-5-(2-pyridinyl)-1,3-thiazol-2-amines derivatives as NPY Y5 antagonists. Bioorg. Med. Chem. Lett. 2010, 20, 4741–4744. 10.1016/j.bmcl.2010.06.140. [DOI] [PubMed] [Google Scholar]
- Lowe J. A.; Hou X.; Schmidt C.; David Tingley F.; McHardy S.; Kalman M.; DeNinno S.; Sanner M.; Ward K.; Lebel L.; Tunucci D.; Valentine J. The discovery of a structurally novel class of inhibitors of the type 1 glycine transporter. Bioorg. Med. Chem. Lett. 2009, 19, 2974–2976. 10.1016/j.bmcl.2009.04.035. [DOI] [PubMed] [Google Scholar]
- Soth M. J.; Jones P.; Ray J.; Liu G.; Le K.; Cross J.. Imidazole derivatives as inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease and their preparation. US20180057507, 2018.
- Liu S.; Tong B.; Mason J. W.; Ostrem J. M.; Tutter A.; Hua B. K.; Tang S. A.; Bonazzi S.; Briner K.; Berst F.; Zécri F. J.; Schreiber S. L. Rational Screening for Cooperativity in Small-Molecule Inducers of Protein–Protein Associations. J. Am. Chem. Soc. 2023, 145, 23281. 10.1021/jacs.3c08307. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Moustakas D. T.; Dipietro L. V.; Schoenherr H.; Toure B.-B.; Walters W. P.; Murcko M. A.; Kurukulasuriya R.; Pierce L. C. T.; Giordanetto F.; Shan Y.; Sagawa S.; Krilov G.; McRobb F.; Therrien E.. Preparation of pyrrolo[2,3-d]pyrimidine and pyrrolo[2,1-f][1,2,4]triazine compounds as Src inhibitors and uses thereof. WO2022109551, 2022.
- Li Y.; Feng J.; Huang F.; Baell J. B. Synthesis of 3-Azabicyclo[3.1.0]hexane Derivates. Chem. Eur. J. 2023, 29, e202301017 10.1002/chem.202301017. [DOI] [PubMed] [Google Scholar]
- Axten J. M.; Cheung M.; Demartino M. P.; Guan H. A.; Hu Y.; Miller A. B.; Qin D.; Wu C.; Zhang Z.; Lin X.. Preparation of substituted phenylpyridinylmethylpiperidines, phenylpyridinylmethylpiperazines and their analogs as furin inhibitors. WO2019215341, 2019.
- Estrada A.; Liu W.; Patel S.; Siu M.. Preparation of pyrazolylpyridinamine derivatives for use as DLK inhibitors. WO2014111496, 2014.
- Flohr A.; Mayweg A.; Trainor G.; Epstein D. M.; O’Connor M.; Buck E.; Arista L.. Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use. WO2020068867, 2020.
- Lindsley C. W.; Conn P. J.; Weaver C. D.; Niswender C. M.; Williams R.; Jones C. K.; Sheffler D. J.. 3-Azabicyclo[3.1.0]hexane derivatives as GlyT1 inhibitors and their preparation and use for the treatment of diseases. WO2010078348, 2010.
- Nam G. S.; Choi K. I.; Pae A. N.; Seo S. H.; Choo H. A.; Keum G. C.; Kim J. H.. Preparation of novel 6-pyrazolylamido-3-substituted azabicyclo[3.1.0]hexane compounds as calcium channel inhibitors. US20140343295, 2014.
- Lathrop S. P.; Mlinar L. B.; Manjrekar O. N.; Zhou Y.; Harper K. C.; Sacia E. R.; Higgins M.; Bogdan A. R.; Wang Z.; Richter S. M.; Gong W.; Voight E. A.; Henle J.; Diwan M.; Kallemeyn J. M.; Sharland J. C.; Wei B.; Davies H. M. L. Continuous Process to Safely Manufacture an Aryldiazoacetate and Its Direct Use in a Dirhodium-Catalyzed Enantioselective Cyclopropanation. Org. Process Res. Dev. 2023, 27, 90–104. 10.1021/acs.oprd.2c00288. [DOI] [Google Scholar]
- Wei B.; Hatridge T. A.; Jones C. W.; Davies H. M. L. Copper(II) Acetate-Induced Oxidation of Hydrazones to Diazo Compounds under Flow Conditions Followed by Dirhodium-Catalyzed Enantioselective Cyclopropanation Reactions. Org. Lett. 2021, 23, 5363–5367. 10.1021/acs.orglett.1c01580. [DOI] [PubMed] [Google Scholar]
- Liu W.; Twilton J.; Wei B.; Lee M.; Hopkins M. N.; Bacsa J.; Stahl S. S.; Davies H. M. L. Copper-Catalyzed Oxidation of Hydrazones to Diazo Compounds Using Oxygen as the Terminal Oxidant. ACS Catal. 2021, 11, 2676–2683. 10.1021/acscatal.1c00264. [DOI] [Google Scholar]
- Hatridge T. A.; Wei B.; Davies H. M. L.; Jones C. W. Copper-Catalyzed, Aerobic Oxidation of Hydrazone in a Three-Phase Packed Bed Reactor. Org. Process Res. Dev. 2021, 25, 1911–1922. 10.1021/acs.oprd.1c00165. [DOI] [Google Scholar]
- Hatridge T. A.; Liu W.; Yoo C.-J.; Davies H. M. L.; Jones C. W. Optimized Immobilization Strategy for Dirhodium(II) Carboxylate Catalysts for C–H Functionalization and Their Implementation in a Packed Bed Flow Reactor. Angew. Chem., Int. Ed. 2020, 59, 19525–19531. 10.1002/anie.202005381. [DOI] [PubMed] [Google Scholar]
- Delville M. M. E.; van Hest J. C. M.; Rutjes F. P. J. T. Ethyl diazoacetate synthesis in flow. Beilstein J. Org. Chem. 2013, 9, 1813–1818. 10.3762/bjoc.9.211. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Maurya R. A.; Min K.-I.; Kim D.-P. Continuous flow synthesis of toxic ethyl diazoacetate for utilization in an integrated microfluidic system. Green Chem. 2014, 16, 116–120. 10.1039/C3GC41226A. [DOI] [Google Scholar]
- Müller S. T. R.; Wirth T. Diazo Compounds in Continuous-Flow Technology. ChemSusChem 2015, 8, 245–250. 10.1002/cssc.201402874. [DOI] [PubMed] [Google Scholar]
- Wei B.; Sharland J. C.; Blackmond D. G.; Musaev D. G.; Davies H. M. L. In Situ Kinetic Studies of Rh(II)-Catalyzed C–H Functionalization to Achieve High Catalyst Turnover Numbers. ACS Catal. 2022, 12, 13400–13410. 10.1021/acscatal.2c04115. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wei B.; Sharland J. C.; Lin P.; Wilkerson-Hill S. M.; Fullilove F. A.; McKinnon S.; Blackmond D. G.; Davies H. M. L. In Situ Kinetic Studies of Rh(II)-Catalyzed Asymmetric Cyclopropanation with Low Catalyst Loadings. ACS Catal. 2020, 10, 1161–1170. 10.1021/acscatal.9b04595. [DOI] [Google Scholar]
- Pelphrey P.; Hansen J.; Davies H. M. L. Solvent-free catalytic enantioselective C–C bond forming reactions with very high catalyst turnover numbers. Chem. Sci. 2010, 1, 254–257. 10.1039/c0sc00109k. [DOI] [Google Scholar]
- Davies H. M. L.; Venkataramani C. Dirhodium Tetraprolinate-Catalyzed Asymmetric Cyclopropanations with High Turnover Numbers. Org. Lett. 2003, 5, 1403–1406. 10.1021/ol034002a. [DOI] [PubMed] [Google Scholar]
- Espino C. G.; Fiori K. W.; Kim M.; Du Bois J. Expanding the Scope of C–H Amination through Catalyst Design. J. Am. Chem. Soc. 2004, 126, 15378–15379. 10.1021/ja0446294. [DOI] [PubMed] [Google Scholar]
- Pyo S.-H.; Park J. H.; Chang T.-S.; Hatti-Kaul R. Dimethyl carbonate as a green chemical. Curr. Opin. Green Sustain. Chem. 2017, 5, 61–66. 10.1016/j.cogsc.2017.03.012. [DOI] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The data underlying this study are available in the published article and its Supporting Information.








